Company intelligence / Profile preview
Zucero Therapeutics
Geelong, Victoria, Australiapmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Employees
- ~1
- Development stage
- Phase 2
01
Overview
Pixatimod has been shown to be well tolerated as a single agent in patients with advanced cancer and is currently being tested in combination with the immune checkpoint inhibitor Opdivo® for the treatment of advanced cancer with a focus on pancreatic cancer. It is also in Phase II for Non-Small Cell Lung Cancer.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Modified sugar compoundsImmunomodulatory agents
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Zucero Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zucero Therapeutics.